Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bleximenib - Janssen Research & Development

Next Previous
Drug Profile

Bleximenib - Janssen Research & Development

Alternative Names: JNJ-6617; JNJ-75276617

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Amides; Amines; Antineoplastics; Azetidines; Ethanolamines; Ethers; Fluorobenzenes; Phenols; Small molecules; Spiro compounds; Triazines
  • Mechanism of Action Histone-lysine N-methyltransferase inhibitors; Menin inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 03 Nov 2025 Stichting Hemato-Oncologie voor Volwassenen Nederland plans a phase III trial for Acute Myeloid Leukemia (Combination therapy, Newly diagnosed) in December 2025 (NCT07223814)
  • 24 Jun 2025 Chemical structure information added.
  • 12 Jun 2025 Efficacy and adverse events data from phase I trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) released by Johnson & Johnson

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top